Promising tool to combat cachexia-induced muscle wasting discovered
Cachexia, a syndrome characterized by rapid weight loss and muscle deterioration, is a major cause of death among patients suffering from diseases like cancer, AIDS and chronic infection. Now, a newly published study by 海角社区 researchers shows that a low dose of Pateamine A is effective at preventing cancer-induced muscle wasting, which may lead to cachexia-fighting drugs.
Researchers from 海角社区 block onset of cachexia in animal models
Cachexia, a syndrome characterized by rapid weight loss and muscle deterioration, is a major cause of death among patients suffering from diseases like cancer, AIDS and chronic infection. In fact, 30 per cent of cancer-related deaths are the result of cachexia-induced muscle loss rather than the primary malignancy. And while scientists are making strides in gaining a better understanding of this deadly condition, no effective anti-cachectic therapies exist to date. However, a newly published study by 海角社区 University researchers shows that a low dose of Pateamine A (PatA) is effective at preventing cancer-induced muscle wasting 鈥� findings that could someday point to the development of cachexia-fighting drugs.
鈥淭o this day, when patients are diagnosed with cachexia, they鈥檙e sent to palliative care. Their illness is no longer treatable. They start losing muscle, including that which is in the lungs and they eventually die by asphyxia,鈥� explained Dr. Imed Gallouzi, the paper鈥檚 senior author and Associate Professor in 海角社区鈥檚 Dept. of Biochemistry and researcher at the Goodman Cancer Research Centre. 鈥淚t鈥檚 not that there are ineffective drugs out there, it鈥檚 that there are no approved drugs to treat this condition right now.鈥�
Recently, compounds like PatA, a natural derivative of marine sponge known to interfere with protein production inside the cell and Episilvestrol (Epi), a plant compound, have been found to block tumor growth. Since tumors and inflammation are conditions that lead to muscle wasting, Gallouzi and his team tested the effect of different doses of PatA and Epi as potential anti-cachetic agents.
鈥淲e observed that a low dose of PatA blocks the onset of muscle wasting in two animal models by blocking the expression of factors that promote cachexia,鈥� said Gallouzi. 鈥淧atA was originally identified as an inhibitor of the early steps that lead to protein synthesis inside the cell. As such, however, PatA can be toxic. Surprisingly, when we used this compound at a lower dose, we observed that it prevents cachexia-induced muscle loss, by specifically interfering with the expression of promoters of muscle loss. Now we need to confirm that PatA, and its family of compounds, is effective in blocking muscle wasting in other animal models.鈥�
The findings were published this week in the journal Nature Communications. Co-lead authors are Sergio Di Marco and Anne Cammas, both from 海角社区鈥檚 Dept. of Biochemistry and the Goodman Cancer Research Centre (GCRC). Xian Jin Lian, Erzsebet Nagy Kovacs, Jennifer F. Ma, Derek T. Hall (all from 海角社区 Dept. of Biochemistry/GCRC); Rachid Mazroui (Dept. of Molecular Biology, Medical Biochemistry and Pathology, Centre de Recherche H么pital Saint-Fran莽ois d鈥橝ssise, Le CHUQ); John Richardson (海角社区 Dept. of Neurology and Neurosurgery) and Jerry Pelletier (海角社区 Dept. of Biochemistry/GCRC) also contributed to the work.
听
听
听
听